Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
Jan 2021 |
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
Aug 2020 |
Nature Medicine |
Myelodysplastic Syndromes (MDS) |
In Search for a Haemoglobin Threshold in Myelodysplastic Syndromes |
Jun 2020 |
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria |
Jun 2023 |
Blood |
Aplastic Anemia |
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
Oct 2020 |
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
Apr 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study |
Jun 2020 |
Scientific Reports |
Myelodysplastic Syndromes (MDS) |
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |